Arcus Biosciences Inc. (RCUS)
Arcus Biosciences Statistics
Share Statistics
Arcus Biosciences has 105.84M shares outstanding. The number of shares has increased by 16.37% in one year.
| Shares Outstanding | 105.84M |
| Shares Change (YoY) | 16.37% |
| Shares Change (QoQ) | 15.66% |
| Owned by Institutions (%) | 91.8% |
| Shares Floating | 64.9M |
| Failed to Deliver (FTD) Shares | 34 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 8.45M, so 7.98% of the outstanding shares have been sold short.
| Short Interest | 8.45M |
| Short % of Shares Out | 7.98% |
| Short % of Float | 14.39% |
| Short Ratio (days to cover) | 9.64 |
Valuation Ratios
The PE ratio is -4.74 and the forward PE ratio is -1.94. Arcus Biosciences's PEG ratio is 0.19.
| PE Ratio | -4.74 |
| Forward PE | -1.94 |
| PS Ratio | 5.2 |
| Forward PS | 1 |
| PB Ratio | 2.77 |
| P/FCF Ratio | -7.62 |
| PEG Ratio | 0.19 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Arcus Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.5, with a Debt / Equity ratio of 0.1.
| Current Ratio | 4.5 |
| Quick Ratio | 4.5 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.18 |
| Debt / FCF | -0.27 |
| Interest Coverage | -82.5 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $411.48K |
| Profits Per Employee | $-451.36K |
| Employee Count | 627 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1M |
| Effective Tax Rate | -0.35% |
Stock Price Statistics
The stock price has increased by -42.84% in the last 52 weeks. The beta is 1.54, so Arcus Biosciences's price volatility has been higher than the market average.
| Beta | 1.54 |
| 52-Week Price Change | -42.84% |
| 50-Day Moving Average | 9.15 |
| 200-Day Moving Average | 14.04 |
| Relative Strength Index (RSI) | 51.13 |
| Average Volume (20 Days) | 1.14M |
Income Statement
In the last 12 months, Arcus Biosciences had revenue of 258M and earned -283M in profits. Earnings per share was -3.14.
| Revenue | 258M |
| Gross Profit | 258M |
| Operating Income | -330M |
| Net Income | -283M |
| EBITDA | -269M |
| EBIT | -279M |
| Earnings Per Share (EPS) | -3.14 |
Balance Sheet
The company has 150M in cash and 48M in debt, giving a net cash position of 102M.
| Cash & Cash Equivalents | 150M |
| Total Debt | 48M |
| Net Cash | 102M |
| Retained Earnings | -1.13B |
| Total Assets | 1.15B |
| Working Capital | 790M |
Cash Flow
In the last 12 months, operating cash flow was -170M and capital expenditures -6M, giving a free cash flow of -176M.
| Operating Cash Flow | -170M |
| Capital Expenditures | -6M |
| Free Cash Flow | -176M |
| FCF Per Share | -1.95 |
Margins
Gross margin is 100%, with operating and profit margins of -127.91% and -109.69%.
| Gross Margin | 100% |
| Operating Margin | -127.91% |
| Pretax Margin | -109.69% |
| Profit Margin | -109.69% |
| EBITDA Margin | -104.26% |
| EBIT Margin | -127.91% |
| FCF Margin | -68.22% |
Dividends & Yields
RCUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RCUS is $27, which is 220.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $27 |
| Price Target Difference | 220.7% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | -0.36 |
| Piotroski F-Score | 3 |